JCIT featured in Dagens Medisin discussing the Advance of the Year: Immunotherapy 2.0
In connection with American Society of Clinical Oncology (ASCO) naming immunotherapy as the Society’s advance of the year, Professor Johanna Olweus and Professor Karl-Johan Malmberg was interviewed by Dagens Medisin, April 12th 2017.
Johanna Olweus and Karl-Johan Malmberg commented on the expanding role of immunotherapy in cancer treatment.
Olweus and her group published an article in Science in 2016 demonstrating that donor-derived T cell repertoires can be utilized to target mutations in cancer cells that are not “seen” by the patient’s own T cells in vivo.
The Malmberg group has developed a platform to differentiate adaptive natural killer (NK) cells with a special ability to recognize and kill cancer cells. The Malmberg lab recently entered into partnership with Fate Therapeutics to develop off-the-shelf NK cell therapy.